Search

Your search keyword '"TEATINI U."' showing total 10 results
Start Over Author "TEATINI U." Topic medicine.medical_specialty
10 results on '"TEATINI U."'

1. Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10 – 12 g/dl

Author

Hörl WH, Locatelli F, Haag Weber M, Ode M, Roth K, Lhotta K, Loipl J, Huspek M, Gstöttenbauer K, Karagyozova R, Monova D, Shikov P, Yovchev T, Bazeva P, Nenchev N, Charasse C, Bockreiss N, Buhl M, Dellanna F, Dragoun GP, Goller M, Klingbeil A, Knee J, Krallinger R, Menzer T, Perschon G, Toussaint K, Wichelhaus T, Kreuzer K, Brückner D, Leistikow F, Marsen T, Sacherer K, Zimmermann U, Kohnle M, Riedasch M, Brehm K, Vogt J, Morgenroth A, Herrnberger S, Zeh M, Dammerboer C, Hofmann T, Kraemer Guth A, Wilpert J, Pröschild F, Krämer B, Lang R, Zanker B, Lubrich Birkner I, Hemstege M, Jäkel D, Perino S, Riedl B, Assenmacher A, Albertazzi A, Colussi G, Garibotto G, Villa G, Gesualdo L, Triolo G, Cusi D, Gallieni M, Quarello F, Malberti F, Tarchini R, Di Iorio BR, Di Luca M, Bordoni E, Brunori G, Della Grotta F, Fracasso A, Guerrini E, Ragaiolo M, Costanzo R, Teatini U, Dimitrov S, Sikole A, Zabzun M, Janakievska P, Petrovska T, Rzanikoski T, Alceva M, Panova B, Daniewska D, Klatko W, Stryjewski D, Książek A, Kopecka Mechlińska L, Kędzierski P, Nowicki M, Szurkowski M, Papliński M, Trafny R, Kuczera M, Sokalski A, Rydzewski A, Liberek T, Uzar J, Bako GC, Ionescu D, Voiculescu M, Ardelean LC, Pitea IV, Demina L, Borsukov A, Marasaev V, Fedosseev A, Dudar I, Kolesnyk M, Kostynenko T, Kuchma I, Kuriata O, Lesovoy V, Martynyuk L, Nikonenko O., STEFONI, SERGIO, Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K, Lhotta K, Loipl J, Huspek M, Gstöttenbauer K, Karagyozova R, Monova D, Shikov P, Yovchev T, Bazeva P, Nenchev N, Charasse C, Bockreiss N, Buhl M, Dellanna F, Dragoun GP, Goller M, Klingbeil A, Knee J, Krallinger R, Menzer T, Perschon G, Toussaint K, Wichelhaus T, Kreuzer K, Brückner D, Leistikow F, Marsen T, Sacherer K, Zimmermann U, Kohnle M, Riedasch M, Brehm K, Vogt J, Morgenroth A, Herrnberger S, Zeh M, Dammerboer C, Hofmann T, Kraemer-Guth A, Wilpert J, Pröschild F, Krämer B, Lang R, Zanker B, Lubrich-Birkner I, Hemstege M, Jäkel D, Perino S, Riedl B, Assenmacher A, Albertazzi A, Colussi G, Garibotto G, Villa G, Gesualdo L, Triolo G, Cusi D, Gallieni M, Quarello F, Malberti F, Stefoni S, Tarchini R, Di Iorio BR, Di Luca M, Bordoni E, Brunori G, Della Grotta F, Fracasso A, Guerrini E, Ragaiolo M, Costanzo R, Teatini U, Dimitrov S, Sikole A, Zabzun M, Janakievska P, Petrovska T, Rzanikoski T, Alceva M, Panova B, Daniewska D, Klatko W, Stryjewski D, Książek A, Kopecka-Mechlińska L, Kędzierski P, Nowicki M, Szurkowski M, Papliński M, Trafny R, Kuczera M, Sokalski A, Rydzewski A, Liberek T, Uzar J, Bako GC, Ionescu D, Voiculescu M, Ardelean LC, Pitea IV, Demina L, Borsukov A, Marasaev V, Fedosseev A, Dudar I, Kolesnyk M, Kostynenko T, Kuchma I, Kuriata O, Lesovoy V, Martynyuk L, and Nikonenko O

Subjects
Male, Time Factors, Pharmacology, Adult, Aged, Aged, 80 and over, Anemia, Biomarkers, Biosimilar Pharmaceuticals, Chronic Disease, Epoetin Alfa, Erythropoietin, Europe, Female, Hematinics, Hemoglobins, Humans, Injections, Intravenous, Kidney Diseases, Middle Aged, Neoplasms, Prospective Studies, Recombinant Proteins, Thrombosis, Treatment Outcome, Young Adult, 80 and over, Prospective cohort study, HEMOGLOBIN, media_common, General Medicine, Nephrology, Intravenous, medicine.drug, medicine.medical_specialty, Injections, Internal medicine, medicine, media_common.cataloged_instance, ANEMIA, European union, Adverse effect, CHRONIC KIDNEY DISEASE, business.industry, BIOSIMILAR EPOETIN-Α, PRODUCT, Epoetin alfa, medicine.disease, Clinical trial, business, Kidney disease
Abstract

HX575 was approved in the European Union in August 2007 as the first-ever biosimilar epoetin-α product. The present study extended the safety database on HX575 by monitoring adverse events (AEs) in clinical practice. Hemoglobin (Hb) levels and HX575 doses were recorded for the assessment of efficacy. This open, 6-month single-arm study was conducted in 10 European countries with a target enrollment of 1,500 patients with anemia due to chronic kidney disease (CKD). HX575 was intravenously (i.v.) administered aiming at an Hb target of 10 - 12 g/dl. Most patients (92.3%) had already received erythropoiesis stimulating agents (ESAs) treatment before enrolment into this study; the recorded treatments mainly comprised i.v. or subcutaneous (s.c.) administration of epoetin-α, epoetin-β or darbepoetin. The study period covered 770 patient years. The observed AE profile was in line with expectations for this patient population. Thrombotic vascular events (TVEs) were reported in 11.9% of patients (0.2612 per patient year). Tumor incidence was 1.4% (0.0299 per patient year). No subject developed anti-epoetin antibodies. Mean Hb levels were effectively maintained between 11.2 and 11.3 g/dl following the conversion from a broad spectrum of pre-study ESA treatments with stable overall mean i.v. HX575 doses. The proportion of patients within the Hb target range increased from 57.5% at baseline to 66.8% at study end.

Published
2012
Full Text
View/download PDF

2. Awareness of kidney diseases in general population and in high school students. Italian report for World Kidney Days 2010-2011

Author

Apperti, V, Auricchio, Mr, Barbato, A, Bedani, Pl, Bellinghieri, G, Costantino, G, Boggi, R, Bonomini, M, Calabria, L, Calabria, M, Grimaldi, M, Capuano, M, Terribile, M, Caputo, C, Castellino, S, Centrone, E, Ciccarelli, M, Cicchetti, T, Costantino, E, D'Amaro, E, Dagostino, F, Napolitano, F, Bonifati, C, Dal Canton, A, Esposito, P, Delgado, G, D'Apice, L, Di Luca, M, Farfaglia, P, Cantù, P, Farina, M, Fasianos, E, Feriozzi, S, Galeotti, P, Fiorini, F, Frattolillo, P, Garibotto, Giacomo, Giannattasio, M, Detomaso, F, Latino, A, Li Vecchi, M, Maffucci, G, Anelli, Am, Mangano, S, Meneghel, G, Morrone, L, Mura, C, Novizio, D, Paglia, S, Cardone, F, Parsi, R, Pizzini, M, Polito, P, Prati, E, Brognoli, M, Rubino, F, Turchetta, L, Parravano, M, Sambati, M, Sicignano, M, Tarchini, R, Teatini, U, Gallieni, M, Colussi, G, Limido, A, Pozzi, C, Spotti, D, Brancaccio, D, Traversari, L, Venditti, G, Aucella, F, Garganico, R, Giovanni Rotondo, S, Cenerelli, S, Bozzi, M, Petrarulo, F, Casu, Md, Cavatorta, F, Montesano, C, Ferrara, Dd, Mazzola, Ma, De Simone, W, Del Rosso, G, Sozzo, Ee, Mangione, D, Emiliani, G, Fasianos, R, Ganadu, M, Garibotto, G, Lusenti, T, Manno, C, Orbello, G, Rondanini, V, Russo, D, Battaglia, Y, Sarli, P, Sozzo, E, Napoli, M, Valentini, Wd, Viganò, L., Y., Battaglia 1, L., Russo 1, R., Spadola 1, Russo, Domenico, Battaglia, Y, Russo, L., and Spadola, R.

Subjects
Male, Nephrology, Health Knowledge, Attitudes, Practice, Pediatrics, Kidney Disease, Global Health, Surveys and Questionnaires, Prevalence, Global health, Surveys and Questionnaire, Young adult, Reagent Strips, Practice, Kidney, education.field_of_study, Health Knowledge, Urinalysi, Awareness, Middle Aged, Proteinuria, Treatment Outcome, medicine.anatomical_structure, Italy, Hypertension, Kidney Diseases, Female, Reagent Strip, Student, Comprehension, Human, Adult, medicine.medical_specialty, Adolescent, Population, Health knowledge, Health literacy, Health Promotion, Urinalysis, Young Adult, Terminology as Topic, Internal medicine, medicine, Humans, Students, education, Aged, business.industry, Blood Pressure Determination, Health Literacy, Adolescent Behavior, Awarene, Health promotion, Attitudes, Family medicine, business
Published
2012
Full Text
View/download PDF

3. Clinical policies on the management of chronic kidney disease patients in Italy

Author

SIR SIN STUDY INVESTIGATORS ACCIARRI P, MENEGATO MA, ANCARANI E, ANDREUCCI V, ANTONELLI A, AURICCHIO MR, BALDUCCI A, BASSI A, BATTAGLIA G, BELLINGHERI G, BELTRAME A, BIAGINI M, BONFANTE L, BONOFIGLIO R, BONOMINI M, BORGHI M, BRIGANTE M, BUCCIANTI G, BUONGIORNO E, CABIBBE M, CANCARINI G, CAPISTRANO M, CAPPELLI G, CAPUANO M, CASCONE C, CATIZONE L, CATUCCI AE, CAVATORTA F, CHIARINOTTI D, CICCHETTI T, CONCAS G, CONCETTI M, CONTE F, CONTI M, CORATELLI P, CORTI MM, COSTANZO R, DAL CANTON A, D'APICE L, DAVID S, DE CRISTOFARO V, DEFERRARI G, DELLA GROTTA F, DE NICOLA, Luca, DE SANTO NG, DE SIMONE W, DI DANIELE N, DI GIULIO S, DI LANDRO D, DI LUZIO V, DI MAGGIO A, FAGUGLI R, FARINA M, FERIANI M, GALLIENI M, GAMBARO G, GIORDANO R, GRECO S, GRILLO C, HUBER W, LIUZZO G, LOCATELLI F, LOMBARDI L, LOPEZ T, MALBERTI F, MANCINI W, MANENTI F, MANISCO G, MARROCCO A, MATOCCI G, MERICO G, MESSA P, MINUTOLO, Roberto, MONARDO P, MORICONI L, MURRONE P, NARDO A, NASO A, NOBILE R, PANARELLO G, PAONE A, PARRAVANO M, PEDRINI L, PIAZZA V, PISTIS R, PROCIDA M, QUARELLO F, RAPISARDA F, RICCIARDI B, RINDI P, RONCO C, ROTOLO U, RUSSO G, SARANITI A, SASDELLI M, SAVICA V, SCANZIANI R, SIDOTI A, SPOTTI D, STALTERI A, STEFONI S, STELLA A, STRIPPOLI P, TEATINI U, TEODORO C, TOZZO C, TRIOLO G, ZOCCALI C., Locatelli F, Zoccali C, Acciarri P, Menegato MA, Ancarani E, Andreucci V, Antonelli A, Auricchio MR, Balducci A, Bassi A, Battaglia G, Bellingheri G, Beltrame A, Biagini M, Bonfante L, Bonofiglio R, Bonomini M, Borghi M, Brigante M, Buccianti G, Buongiorno E, Cabibbe M, Cancarini G, Capistrano M, Cappelli G, Capuano M, Cascone C, Catizone L, Catucci AE, Cavatorta F, Chiarinotti D, Cicchetti T, Concas G, Concetti M, Conte F, Conti M, Coratelli P, Corti MM, Costanzo R, Dal Canton A, D'Apice L, David S, De Cristofaro V, Deferrari G, Della Grotta F, De Nicola L, De Santo NG, De Simone W, Di Daniele N, Di Giulio S, Di Landro D, Di Luzio V, Di Maggio A, Fagugli R, Farina M, Feriani M, Gallieni M, Gambaro G, Giordano R, Greco S, Grillo C, Huber W, Liuzzo G, Lombardi L, Lopez T, Malberti F, Mancini W, Manenti F, Manisco G, Marrocco A, Matocci G, Merico G, Messa P, Minutolo R, Monardo P, Moriconi L, Murrone P, Nardo A, Naso A, Nobile R, Panarello G, Paone A, Parravano M, Pedrini L, Piazza V, Pistis R, Procida M, Quarello F, Rapisarda F, Ricciardi B, Rindi P, Ronco C, Rotolo U, Russo G, Saraniti A, Sasdelli M, Savica V, Scanziani R, Sidoti A, Spotti D, Stalteri A, Stefoni S, Stella A, Strippoli P, Teatini U, Teodoro C, Tozzo C, Triolo G., SIR SIN STUDY INVESTIGATORS ACCIARRI, P, Menegato, Ma, Ancarani, E, Andreucci, V, Antonelli, A, Auricchio, Mr, Balducci, A, Bassi, A, Battaglia, G, Bellingheri, G, Beltrame, A, Biagini, M, Bonfante, L, Bonofiglio, R, Bonomini, M, Borghi, M, Brigante, M, Buccianti, G, Buongiorno, E, Cabibbe, M, Cancarini, G, Capistrano, M, Cappelli, G, Capuano, M, Cascone, C, Catizone, L, Catucci, Ae, Cavatorta, F, Chiarinotti, D, Cicchetti, T, Concas, G, Concetti, M, Conte, F, Conti, M, Coratelli, P, Corti, Mm, Costanzo, R, DAL CANTON, A, D'Apice, L, David, S, DE CRISTOFARO, V, Deferrari, G, DELLA GROTTA, F, DE NICOLA, Luca, DE SANTO, Ng, DE SIMONE, W, DI DANIELE, N, DI GIULIO, S, DI LANDRO, D, DI LUZIO, V, DI MAGGIO, A, Fagugli, R, Farina, M, Feriani, M, Gallieni, M, Gambaro, G, Giordano, R, Greco, S, Grillo, C, Huber, W, Liuzzo, G, Locatelli, F, Lombardi, L, Lopez, T, Malberti, F, Mancini, W, Manenti, F, Manisco, G, Marrocco, A, Matocci, G, Merico, G, Messa, P, Minutolo, Roberto, Monardo, P, Moriconi, L, Murrone, P, Nardo, A, Naso, A, Nobile, R, Panarello, G, Paone, A, Parravano, M, Pedrini, L, Piazza, V, Pistis, R, Procida, M, Quarello, F, Rapisarda, F, Ricciardi, B, Rindi, P, Ronco, C, Rotolo, U, Russo, G, Saraniti, A, Sasdelli, M, Savica, V, Scanziani, R, Sidoti, A, Spotti, D, Stalteri, A, Stefoni, S, Stella, A, Strippoli, P, Teatini, U, Teodoro, C, Tozzo, C, Triolo, G, and Zoccali, C.

Subjects
Nephrology, medicine.medical_specialty, Referral, Anemia, medicine.medical_treatment, Context (language use), Metabolic Diseases, Internal medicine, Surveys and Questionnaires, Italian Society of Nephrology, chronic kidney disease, questionnaire, medicine, Humans, Intensive care medicine, Dialysis, Settore MED/14 - Nefrologia, Transplantation, business.industry, Guideline, medicine.disease, Italy, Chronic Disease, Kidney Diseases, Hemodialysis, Guideline Adherence, business, Kidney disease
Abstract

BACKGROUND: Recent studies have indicated that the implementation of international guidelines for the management of renal patients is suboptimal in Italy. The Italian Society of Nephrology (SIN) decided to undertake a multicentre study to obtain a clear picture of clinical policies on chronic kidney disease (CKD) in Italy. METHODS: A 76-item structured questionnaire, designed to evaluate the organization of clinical care, was administered to the director of each participating centre, within the context of a large observational trial in 100 Italian nephrology centres, collecting information on newly diagnosed CKD patients (K/DOQI stage 3-5) on conservative treatment. This paper reports the questionnaire results related to management of anaemia and bone metabolism disorders; assessment of renal function; creation of a vascular access for dialysis and referral of patients to a nephrologist. RESULTS: Clinical policies at the centre level deviated from guideline recommendations in 70% (timing of vascular access creation) to 25% (assessment of iron deficiency) of centres. Assessment of renal function differed from the recommended approach in 30% of centres; clinical policies related to anaemia and bone disease did not coincide with guideline standards in 50 and 40% of centres, respectively. Directors of renal unit estimates indicate that the creation of a vascular access occurs very late in 38% of patients and that referral to a nephrologist is late in approximately 40% of cases. CONCLUSION: This survey in Italy highlights important deviations of clinical policies at the centre level from guideline recommendations.

Published
2008

4. High Efficiency Hemofiltration

Author

E. Minetti, Teatini U, Luigi Minetti, Giovanni Civati, Guastoni C, Perego A, and Perrino Ml

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Hemofiltration, Medicine, business, Intensive care medicine
Published
2015
Full Text
View/download PDF

5. Old and New Perspectives on Peritoneal Dialysis in Italy Emerging from the Peritoneal Dialysis Study Group Census

Author

Marinangeli, G, Cabiddu, G, Neri, L, Viglino, G, Russo, R, Teatini, U, Bonfante, Luciana, Italian Society of Nephrology Peritoneal Dialysis Study Group, Marinangeli, G, Cabiddu, G, Neri, L, Viglino, G, Russo, R, Teatini, U on behalf of the Italian Society of Nephrology Peritoneal Dialysis Group including, and Vezzoli, G

Subjects
medicine.medical_specialty, medicine.medical_treatment, Peritonitis, Peritoneal dialysis, Peritoneal Dialysis, Continuous Ambulatory, Surveys and Questionnaires, Internal medicine, medicine, Humans, Dialysis, business.industry, Incidence, Incidence (epidemiology), Censuses, Peritoneal Fibrosis, Original Articles, General Medicine, medicine.disease, Surgery, Survival Rate, Transplantation, Catheter, Italy, Nephrology, Ambulatory, Hemodialysis, business, Peritoneal Dialysis
Abstract

Background To understand how peritoneal dialysis (PD) was being used in Italy in 2005 and 2008, a census of all centers was carried out. Methods In 2005 and 2008, data were collected from, respectively, 222 and 223 centers, with respect to 4432 and 4094 prevalent patients. Results In the two periods, the PD incidence remained stable (24.3% vs 22.9%), varying from center to center. Continuous ambulatory PD (CAPD) was the main initial method (55%), but APD was more widespread among prevalent patients (53%). Among patients returning to dialysis from transplantation (Tx), PD was used in 10%. The use of incremental CAPD increased significantly from 2005 to 2008, in terms both of the number of centers (27.0% vs 40.9%) and of patients (13.6% vs 25.7%). Late referrals remained stable at 28%, with less use of PD. The overall drop-out rate (episodes/100 patient–years) remained unchanged (31.0 vs 32.8), with 13.1 and 12.9 being the result of death, and 11.8 and 12.4 being the result of a switch to hemodialysis, mainly after peritonitis. A dialysis partner was required by 21.8% of the PD patients. The incidence of peritonitis was 1 episode in 36.5 and 41.1 patient–months, with negative cultures occurring in 17.1% of cases in both periods. The incidence of encapsulating peritoneal sclerosis (episodes/100 patient–years) was 0.70, representing 1.26% of patients treated. The catheter types used and the sites and methods of insertion varied widely from center to center. Conclusions These censuses confirm the good results of PD in Italy, and provide insight into little-known aspects such as the use of incremental PD, the presence of a dialysis partner, and the incidence of encapsulating peritoneal sclerosis.

Published
2012

6. Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy

Author

De Nicola, Luca, Provenzano, Michele, Chiodini, Paolo, D'Arrigo, Graziella, Tripepi, Giovanni, Del Vecchio, Lucia, Conte, Giuseppe, Locatelli, Francesco, Zoccali, Carmine, Minutolo, RobertoAcciarri P, Adorati, M, Ancarani, E, Andreucci, V, Antonelli, A, Auricchio, Mr, Balducci, A, Bassi, A, Battaglia, G, Bellingheri, G, Beltrame, A, Biagini, M, Bonfante, L, Bonofiglio, R, Bonomini, M, Borghi, M, Brigante, M, Buccianti, G, Buongiorno, E, Cabibbe, M, Cancarini, Giovanni, Capistrano, M, Cappelli, G, Capuano, M, Cascone, C, Catizone, L, Catucci, Ae, Cavatorta, F, Chiarinotti, D, Cicchetti, T, Concas, G, Concetti, M, Conte, F, Conte, G, Conti, M, Coratelli, P, Corti, Mm, Costanzo, R, Dal Canton, A, D'Apice, L, David, S, De Cristofaro, V, Deferrari, G, Della Grotta, F, De Santo NG, De Simone, W, Di Daniele, N, Di Giulio, S, Di Landro, D, Di Luzio, V, Di Maggio, A, Fagugli, R, Farina, M, Feriani, M, Gallieni, M, Gambaro, G, Giordano, R, Greco, S, Grillo, C, Huber, W, Liuzzo, G, Locatelli, F, Lombardi, L, Lopez, T, Malberti, F, Mancini, W, Manenti, F, Manisco, G, Marrocco, A, Matocci, G, Merico, G, Messa, P, Minutolo, R, Monardo, P, Moriconi, L, Murrone, P, Nardo, A, Naso, A, Nobile, R, Panarello, G, Paone, A, Parravano, M, Pedrini, L, Piazza, V, Pistis, R, Procida, M, Quarello, F, Rapisarda, F, Ricciardi, B, Rindi, P, Ronco, C, Rotolo, U, Russo, G, Santoro, D, Saraniti, A, Sasdelli, M, Savica, V, Scanziani, R, Sidoti, A, Spotti, D, Stalteri, A, Stefoni, S, Stella, A, Strippoli, P, Teatini, U, Teodoro, C, Tozzo, C, Triolo, G, Zoccali, C., De Nicola, L, Provenzano, M, Chiodini, P, D'Arrigo, G, Tripepi, G, Del Vecchio, L, Conte, G, Locatelli, F, Zoccali, C, and Minutolo, R

Subjects
Male, Nephrology, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Medicine (miscellaneous), Kidney Function Tests, Severity of Illness Index, chemistry.chemical_compound, Endocrinology, Risk Factors, Chronic kidney disease, 80 and over, Prospective Studies, Renal Insufficiency, Chronic, Prospective cohort study, Cardiovascular risk, Cholesterol, ESRD, LDL, Renal clinic, Nutrition and Dietetics, Cardiology and Cardiovascular Medicine, Aged, 80 and over, Medicine (all), Middle Aged, Prognosis, Diabetes and Metabolism, Italy, Cardiovascular Diseases, Female, Glomerular Filtration Rate, medicine.medical_specialty, Renal function, Median follow-up, Internal medicine, Diabetes mellitus, medicine, Humans, Renal replacement therapy, Renal Insufficiency, Chronic, Aged, business.industry, Cholesterol, LDL, medicine.disease, chemistry, business, Kidney disease
Abstract

Background and aims The prognostic role of LDL in non-dialysis chronic kidney disease (CKD) is still undefined. We addressed this question in a multicenter prospective study including patients referred to nephrologist for management. Methods and results 1306 patients with CKD stage III–V were studied at basal visit in 79 Italian nephrology clinics in 2004–2006, and then followed for survival analyses. Study endpoints were incident cardiovascular -CV events (fatal and major non-fatal) and renal events (start of renal replacement therapy or eGFR halving). Mean age was 67.6 ± 11.8 years, male 65%, diabetes 25%, CV disease 27%, and eGFR 35.8 ± 12.5 mL/min/1.73 m 2 . LDL was 119 ± 40 mg/dL, with high levels in 50.1% and 82.8% defined on the basis of the individual CV risk profile estimated according to ATPIII 2001 and ESC 2012 guidelines (LDL 100 to 160, and >70 or >100 mg/dL, respectively). Over a median follow up of 2.87 years, 178 CV and 181 renal events occurred. At multivariable Cox analyses, CV risk linearly increased with higher LDL (hazard ratio-HR per 40 mg/dL higher LDL: 1.20, 95% confidence intervals-CI 1.03–1.39); risk doubled when considering high LDL defined according to ESC 2012 (HR 2.37, 95%CI 1.39–4.03) while this association was not significant when considering the higher threshold levels of ATPIII 2001 (HR 1.10, 95%CI 0.82–1.49). No association emerged between LDL and renal risk. Conclusion In non-dialysis CKD patients, CV risk increases linearly with higher LDL and is more than doubled when considering the lower threshold values currently indicated for defining optimal LDL level.

Published
2015

7. Long-Term Clinical Results with High-Efficiency Hemofiltration

Author

Civati G, Perego A, Guastoni C, F. Zoppi, M. Giachetti, Teatini U, and Luigi Minetti

Subjects
medicine.medical_specialty, Inulin Clearance, Large molecular weight, business.industry, medicine.medical_treatment, Uremic toxicity, Urology, Renal function, Hematology, General Medicine, Nephrology, Hemofiltration, medicine, Hemodialysis, Intensive care medicine, business
Abstract

Uremic toxicity is widely thought to be caused by the retention of a large spectrum of solutes, ranging from small to large molecular weight. Hemodialysis (HD), although achieving a high clearance of

Published
1983
Full Text
View/download PDF

8. Uremic Polyneuropathy Can Be Cured by High-Efficiency Hemofiltration

Author

Teatini U, D. D’Urso, V. Grassi, Luigi Minetti, Perego A, Civati G, and Guastoni C

Subjects
medicine.medical_specialty, Resuscitation, business.industry, medicine.medical_treatment, Hematology, General Medicine, medicine.disease, Surgery, Uremic polyneuropathy, Peripheral neuropathy, Nephrology, Hemofiltration, medicine, sense organs, Renal replacement therapy, skin and connective tissue diseases, business, Polyneuropathy
Abstract

13 patients under artificial renal replacement therapy have been studied as to the changes of electromyographic patterns and peripheral neuropathy symptoms. 10 patients have been treated by high-effic

Published
1983
Full Text
View/download PDF

9. Erythrocyte ferritin in patients on chronic hemodialysis treatment

Author

Giovanni Civati, Luigi Minetti, A. Piperno, Perrino Ml, Teatini U, Perego A, Guastoni C, Brunati C, G. Fiorelli, Brunati, C, Piperno, A, Guastoni, C, Perrino, M, Civati, G, Teatini, U, Perego, A, Fiorelli, G, and Minetti, L

Subjects
Adult, Male, medicine.medical_specialty, Resuscitation, Erythrocytes, Anemia, medicine.medical_treatment, Iron, Gastroenterology, Bone Marrow, Renal Dialysis, Internal medicine, medicine, Humans, Erythropoiesis, Chronic hemodialysis, Serum ferritin, Aged, Anemia, Hypochromic, Ferritin, biology, business.industry, Iron Deficiencies, Iron deficiency, Middle Aged, medicine.disease, Erythrocyte, Red blood cell, medicine.anatomical_structure, Ferritins, Immunology, biology.protein, Female, Hemodialysis, MED/09 - MEDICINA INTERNA, business, Human
Abstract

Serum ferritin (SF) and erythrocyte ferritin (EF) were evaluated in 35 patients on chronic hemodialysis treatment (CHD), in 45 healthy subjects and in 22 nonnephropathic females with iron deficiency anemia. Twenty-five CHD patients with basal SF less than 500 micrograms/l were treated orally with 200 mg of Fe2+ for 2 months and the positive (hemoglobin increase greater than 1 g/dl) or negative response to the therapy was correlated to the basal levels of SF and EF. Three groups of CHD patients could be defined on the basis of their basal SF levels (hypo-, normo- or hyperferritinemic). Nine patients with increased SF levels had also EF levels significantly higher than the other CHD patients and controls since they were probably iron-overloaded. In the other 2 groups of CHD patients, EF levels were significantly higher than in controls for each level of SF probably because of the reduced utilization of iron by uremic bone marrow. Among the 25 treated CHD patients, only 5 responded to the therapy: 3 were hypoferritinemic while the other 2 responders had basal SF within the normal range. Four hypoferritinemic patients did not respond to the therapy. Four out of five responders had the lowest EF levels among CHD patients. EF measurement could be an important and useful test in detecting the presence of an iron deficiency erythropoiesis in CHD patients.

10. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology

Author

Piergiorgio Messa, Giuseppe Vezzoli, Mario Cozzolino, Ciro Esposito, Patrizia Ondei, Giovanni Cancarini, Antonio Bellasi, Francesco Locatelli, Giuseppe Pontoriero, Marzia Pasquali, Carlo Guastoni, Fabio Malberti, Ugo Teatini, Bellasi, A., Cozzolino, M., Malberti, F., Cancarini, G., Esposito, C., Guastoni, C. M., Ondei, P., Pontoriero, G., Teatini, U., Vezzoli, G., Pasquali, M., Messa, P., and Locatelli, F.

Subjects
Nephrology, medicine.medical_specialty, Calcimimetic, medicine.medical_treatment, Population, urologic and male genital diseases, Chronic kidney disease-mineral and bone disorder, Internal medicine, CKD-MBD, medicine, Humans, Position papers and Guidelines, Intensive care medicine, education, Dialysis, Chronic Kidney Disease-Mineral and Bone Disorder, Etelcalcetide, education.field_of_study, business.industry, medicine.disease, female genital diseases and pregnancy complications, Secondary hyperparathyroidism, Italy, Position paper, Cinacalcet, Peptides, business, PTH, Kidney disease
Abstract

Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results